Federico Hinestrosa, MD
Infectious Disease · Orlando, FLNPI 1427215557
Payments from drug & device makers
Across 1,366 payments — averaging $3713.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$4.2M
- GSK$271K
- AbbVie$207K
- Gilead$160K
- Roche Molecular Systems, Inc.$123K
- Viiv Healthcare Company$58K
- plus $12K from 19 others
Across 23 payments — averaging $438.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$9K
- Viiv Healthcare Company$2K
What the payments were for
- Consulting fees$14,4205%
- Speaking & faculty fees$208,86176%
- Travel & lodging$28,66910%
- Food & beverage$23,7249%
- Education$2540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 312 | $4,241,015 |
| GSK | 58 | $271,371 |
| AbbVie(2 entities) | 115 | $206,941 |
| Gilead | 376 | $160,440 |
| Roche Molecular Systems, Inc. | 19 | $122,963 |
| Viiv Healthcare Company | 297 | $58,456 |
| Theratechnologies Inc. | 59 | $10,083 |
| Johnson & Johnson | 84 | $1,148 |
| EMD Serono, Inc. | 9 | $156 |
| Janssen Products, LP | 3 | $140 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $87 |
| Kowa Pharmaceuticals America, Inc. | 5 | $85 |
| Hologic Sales And Service, LLC | 4 | $78 |
| Insmed, Inc. | 4 | $67 |
| Napo Pharmaceuticals Inc | 3 | $49 |
| Pfizer | 2 | $32 |
| Amarin Pharma, Inc. | 2 | $31 |
| Paratek Pharmaceuticals, Inc. | 2 | $31 |
| VBI Vaccine (delaware) Inc. | 1 | $25 |
| Redhill Biopharma Inc. | 1 | $24 |
| Tolmar, Inc. | 1 | $23 |
| Mylan Pharmaceuticals Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $17 |
| Melinta Therapeutics, LLC | 1 | $15 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,073,307 in reported general payments places this provider in the 95th percentile of 669 infectious disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 1,431 | $5,822,855 |
| DovatoDolutegravir Sodium/Lamivudine | 503 | $1,579,482 |
| TivicayDolutegravir Sodium | 274 | $707,880 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 124 | $607,506 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 142 | $595,894 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 131 | $498,625 |
| PrezcobixDarunavir/Cobicistat | 191 | $465,504 |
| JulucaDolutegravir/Rilpivirine | 96 | $367,989 |
| DescovyEmtricitabine/Tenofov Alafenam | 140 | $360,386 |
| RukobiaFostemsavir Tromethamine | 24 | $239,232 |
| PifeltroDoravirine | 118 | $211,711 |
| Egrifta SvTesamorelin Acetate | 19 | $133,914 |
| IsentressRaltegravir Potassium | 51 | $98,329 |
| CabenuvaCabotegravir/Rilpivirine | 14 | $91,587 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 18 | $71,450 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $160,440 | $6,779,1361,713 claims |
| Viiv Healthcare CompanyDovato, Tivicay, Juluca, Rukobia, Cabenuva | $58,456 | $3,057,620929 claims |
| Janssen Products, LPSymtuza | $140 | $607,506124 claims |
| Johnson & JohnsonPrezcobix | $1,148 | $465,504191 claims |
| MerckPifeltro, Isentress | $4,241,015 | $310,040169 claims |
| Theratechnologies Inc.Egrifta Sv | $10,083 | $133,91419 claims |
| Napo Pharmaceuticals IncMytesi | $49 | $67,34217 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $87 | $44,00014 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $85 | $3,53912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 669 infectious disease providers in Florida.
Other infectious disease in Orlando
- Charlotte-Paige RolleOrlando$6M
- Edwin DejesusOrlando$5.9M
- Roberto OrtizOrlando$1.6M
- Kenneth AlexanderOrlando$474K
- Vincent HsuOrlando$222K
- Erick SuarezOrlando$127K
- Moti RamgopalFort Pierce$13.5M
- Larry BushAtlantis$9.3M
- Olayemi OsiyemiWest Palm Beach$8.8M
- Dushyantha JayaweeraMiami$5.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.